Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial-Reference-Cited by-同舟云学术

Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial

Published:2017-08 Issue: Volume:400 Page:276-281
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Montagna Emilia,Palazzo Antonella,Maisonneuve Patrick,Cancello Giuseppe,Iorfida Monica,Sciandivasci Angela,Esposito Angela,Cardillo Anna,Mazza Manuelita,Munzone Elisabetta,Lai Antonella,Goldhirsch Aron,Colleoni Marco

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference33 articles.

1. Pharmacokinetics and bioavailability of cyclophosphamide from oral formulations;Wagner;Arzneimittelforschung,1984

2. Comparison of intravenous and oral high-dose methotrexate in treatment of solid tumours;Christophidis;Br. Med. J.,1979

3. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice;Hanahan;J. Clin. Invest.,2000

4. Clinical overview of metronomic chemotherapy in breast cancer;Munzone;Nat. Rev. Clin. Oncol.,2015

5. Pasquier E Metronomics: towards personalized chemotherapy?;André;Nat. Rev. Clin. Oncol.,2014

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial;Nature Medicine;2024-07-05

2. Optimizing cancer therapy: a review of the multifaceted effects of metronomic chemotherapy;Frontiers in Cell and Developmental Biology;2024-05-15

3. Metronomic chemotherapy in cancer treatment: new wine in an old bottle;Theranostics;2024

4. Dual‑directional effect of vinorelbine combined with cisplatin or fluorouracil on tumor growth and metastasis in metronomic chemotherapy in breast cancer;International Journal of Oncology;2023-12-08

5. Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer;JAMA Oncology;2023-09-01